• Aucun résultat trouvé

Genetics: Alzheimer disease

N/A
N/A
Protected

Academic year: 2022

Partager "Genetics: Alzheimer disease"

Copied!
1
0
0

Texte intégral

(1)

Vol 55: june • juin 2009 Canadian Family PhysicianLe Médecin de famille canadien

603

Genetics

Alzheimer disease

Heather Dorman

MSc

Wendy S. Meschino

MD

Judith Allanson

MD

Sean M. Blaine

MD

Carol Cremin

MSc

Clare A. Gibbons

MS

Christina Honeywell

MSc

Joanne Permaul June C. Carroll

MD

I

nformative genetic testing is currently available to only a small number of families with a his- tory of early-onset (younger than 60 years of age) Alzheimer disease (AD). For these families, the ben- efits of genetic testing are limited and are mainly related to the individual’s perception of the psycho- logical advantages of knowing whether or not he or she is predisposed to develop AD. There remains no cure or effective preventive therapy for AD.

Bottom line. Genetic testing is not feasible for most cases of AD at this time. Apolipoprotein E gene variations alone cannot be used to predict future disease occurrence. Rare families with a history of early-onset AD might be eligible for genetic testing, while families with multiple relatives affected with late-onset AD (60 years of age and older) might be eligible to participate in AD research studies.

The complete Gene Messenger—Alzheimer Disease by the GenetiKit research team is available on CFPlus.*Past Gene Messenger articles can be accessed on-line at www.cfp.ca. On the home page, click on Collections in the left-hand menu, then click on Genetics.

Competing interests None declared

The GenetiKit research team, a group of family physicians, genetic counselors and geneticists, designed the Gene Messenger series to pro- vide practical information to help family physicians and their patients make informed choices about rapidly emerging genetic discoveries.

The series is a collection of up-to-date, definitive, short reviews on genetics topics that have made headlines, and offers recommendations regarding referral for genetic services or testing.

Acknowledgment

Funding was provided by the Canadian Institutes of Health Research.

CFPlus

GO

The English translation of this article, is available at www.cfp.ca. Click on CFPlus to the right of the article or abstract.

*The Gene Messenger on Alzheimer disease is available at www.cfp.ca. Go to the full text of this article on-line, then click on CFPlus in the menu at the top right-hand side of the page.

GENE MESSENGER

For more information on genetics topics, see www.mtsinai.on.ca/FamMedGen/

Genetics

Références

Documents relatifs

Treating all members of a family does not necessarily add much to the fundamental relationship in medicine, which is the relationship between doctor and

If the prin- ciple that family doctors should follow all members of a family is perceived as an obligation, doctors will feel compelled to take on patients they

The GenetiKit research team, a group of family physicians, genetic counselors and geneticists, designed the Gene Messenger series to pro- vide practical information to help

The GenetiKit research team, a group of family physicians, genetic counselors and geneticists, designed the Gene Messenger series to pro- vide practical information to help

The GenetiKit research team, a group of family physicians, genetic counselors and geneticists, designed the Gene Messenger series to pro- vide practical information to help

OBJECTIVE To ascertain the opinions of family physicians about medication adherence in patients with chronic diseases and the role of community pharmacists in improving adherence

The GenetiKit research team, a group of family physicians, genetic counselors and geneticists, designed the Gene Messenger series to pro- vide practical information to help

The GenetiKit research team, a group of family physicians, genetic counselors and geneticists, designed the Gene Messenger series to pro- vide practical information to help